Charles Schwab Investment Management Inc. Buys 70,307 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Charles Schwab Investment Management Inc. lifted its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 16.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 502,204 shares of the company's stock after purchasing an additional 70,307 shares during the period. Charles Schwab Investment Management Inc. owned 1.09% of Pacira BioSciences worth $9,462,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Caitlin John LLC boosted its holdings in Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after buying an additional 1,776 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $62,000 after acquiring an additional 2,749 shares in the last quarter. Virtus Investment Advisers Inc. bought a new position in shares of Pacira BioSciences in the third quarter worth about $98,000. Quest Partners LLC raised its stake in Pacira BioSciences by 137.6% during the 3rd quarter. Quest Partners LLC now owns 9,410 shares of the company's stock valued at $142,000 after purchasing an additional 5,449 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Pacira BioSciences by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after purchasing an additional 918 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.

Remove Ads

Pacira BioSciences Trading Down 0.5 %

Shares of NASDAQ:PCRX traded down $0.12 during trading on Wednesday, reaching $24.42. 1,237,286 shares of the company were exchanged, compared to its average volume of 914,188. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The business's fifty day simple moving average is $24.60 and its 200-day simple moving average is $19.76. The firm has a market capitalization of $1.13 billion, a PE ratio of -12.03 and a beta of 0.86. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $31.67.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC lifted their price objective on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Barclays lifted their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. HC Wainwright increased their price objective on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a "buy" rating in a report on Friday, February 28th. Truist Financial upgraded Pacira BioSciences from a "sell" rating to a "hold" rating and raised their price target for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Finally, Royal Bank of Canada restated a "sector perform" rating and set a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $27.22.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.